3U Translational Cancer

Approximately one in three people in Ireland will develop cancer over their lifetime. Treatments are improving, but cancer is a complex condition and, consequently, developing effective anti-cancer therapies needs expertise across a broad range of disciplines.


The process of translation involves science, medicine and industry partnering to turn research findings into new pharmaceuticals, products or devices for the diagnosis, treatment or prevention of human cancer. In practice, the framework through which research can be translated is a triangle that involves scientists understanding new targets for treatment, clinical researchers measuring the impact on patients and providing relevant samples and industry developing new methods to apply the findings in new diagnostics, drugs and improved therapies.


3U TRANSLATIONAL CANCER research combines scientific and clinical findings, and works with industry to turn these into real, practice-changing methods that could be used against cancer.


By bringing researchers from DCU, RCSI, Maynooth University and industry together as a network, 3U TRANSLATIONAL CANCER draws on a broad range of complementary expertise and allows pooling of resources to accelerate advances. While the grouping has expertise in lung, breast and paediatric cancers, many of the discoveries made apply to other types of cancer as well.




Type 2 diabetes poses a very serious threat in Ireland. Already hundreds of thousands of Irish people…


Tissues in our bodies can become damaged through age, injury or disease, and treatment typically focuses on replacing …


Every moment, billions of proteins are interacting with each other in and on your cells to make your body work. Capturing  …


The 3U Centre of Excellence in Neurodegeneration (COEN) brings together three established and internationally-competitive Centres …


  • Prof. John Crown; Consultant Oncologist at St. Vincent’s University Hospital; DCU;Thomas Baldwin Chair in Translational Cancer Research
  • Professor Martin Clynes; DCU, National Institute for Cellular Biotechnology, School of Biotechnology
  • Dr Paul Dowling; DCU, National Institute for Cellular Biotechnology
  • Dr. Padraig Doolan; DCU, National Institute for Cellular Biotechnology
  • Dr. Colin Clarke; DCU, National Institute for Cellular Biotechnology
  • Dr. AnneMarie Larkin; DCU, National Institute for Cellular Biotechnology
  • Dr Paula Meleady; DCU, National Institute for Cellular Biotechnology
  • Dr Niall Barron; DCU, Director National Institute for Cellular Biotechnology
  • Dr Rosaleen Devery; DCU, School of Biotechnology
  • Dr. Norma O’Donovan; DCU, National Institute for Cellular Biotechnology
  • Dr Bryan Hennessy, RCSI and Consultant Medical Oncologist, Beaumont Hospital, Our Lady of Lourdes Hospital, Drogheda
  • Prof. Elaine Kay; DCU; Biomedical Diagnostics Institute and Consultant Histopathologist and Professor of Academic Pathology in Beaumont Hospital, Dublin and the Royal College of Surgeons in Ireland
  • Professor Ray Stallings; RCSI, Director of Research, Cancer Genetics
  • Dr. Ross Morgan; Consultant in Respiratory Medicine, Beaumont Hospital
  • Dr. Liam Grogan; consultant oncologist, Beaumont Hospital
  • Dr Oscar Breathnach; Consultant Oncologist, Beaumont Hospital
  • Dr Leonie Young; RCSI; Endocrine Oncology Research Group; Associate Professor, Department of Surgery
  • Professor Arnie Hill; RCSI; Department of Surgery; Head of the Medical School, RCSI.
  • Dr Ann Hopkins; RCSI Education & Research Centre, Beaumont Hospital
  • Dr Annette Byrne; RCSI, Department of Physiology & Medical Physics
  • Dr Sally-Ann Cryan; RCSI; Associate Professor, School of Pharmacy
  • Porfessor Jochen Prehn; Director of the Centre for Systems Medicine/ Head of Department, Physiology and Medical Physics
  • Dr. Marcus Rehm; Centre for Systems Medicine, Department of Physiology and Medical Physics